Jim Cramer Calls BillionToOne (BLLN) a “Pretty Darn Good Company”

Jim Cramer, host of Mad Money, recently praised BillionToOne, Inc. (NASDAQ:BLLN) as a "pretty darn good company" during the August 26 lightning round. Cramer stated that despite the stock's high valuation, the company's genetic diagnostic business is comparable to what he used to value at Danaher. The company's second-quarter revenue reached $109.4 million, a 64% increase from the previous year, with gross profit growing to $77.1 million and gross margin rising to 70%.

Income from operations hit $5.5 million, marking a significant improvement from a $1.6 million operating loss a year earlier. Prenatal clinical testing revenue grew by 55% year over year to $94.2 million, while oncology revenue increased by 176% to $13.7 million. The company has reiterated its 2026 revenue guidance of $450 million to $465 million, reflecting a 48% to 52% growth from 2025.

However, Cramer cautioned that the stock remains exposed to potential disappointment in growth or reimbursement issues, as seen in the sharp decline after the earnings release. The company anticipates that claims held during the quarter will be resolved by the second half of 2026, but further delays could impact cash collections.

Despite its rapid growth and expanding margins, BillionToOne, Inc. remains a relatively small player in the oncology market, with production from its $62,000-square-foot oncology facility expected by the end of 2027.